23Aug/13

Astellas' Astagraf XL Launched in U.S. – Analyst Blog – NASDAQ

Astellas’ Astagraf XL Launched in U.S. – Analyst Blog
NASDAQ
Astagraf XL was approved in the U.S. in Jul 2013 for the prophylaxis of organ rejection in patients receiving a kidney transplant used with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction. As per Astellas
ASTELLAS PHARMA INC : ASTAGRAF XLTM (tacrolimus extended-release 4-traders (press release)
Astellas Pharma launches once-daily oral tacrolimus formulation in USPharmaceutical Business Review

all 5 news articles »